Andrew J. Schwab
CIK 1598549 · Co-CEO · last filed 2026-08-31
Andrew J. Schwab is a Co-CEO who has filed 44 SEC Form 4 insider transactions across 16 companies since 2014. The most recent filing shows the insider sold $1.6M of CAMP on Aug 31, 2026. Across all open-market trades the lifetime net is −$183.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $129.5M across reported positions. 71 SEC filings were submitted jointly with SCOTT M ROCKLAGE.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$129.45M
16
44
-$183.43M
Filer Profile
4 EMBARCADERO CENTER, SUITE 3110
SAN FRANCISCO, CA 94111
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CAMP | Director | 2,033,270 | $4.25 | $8.64M | $7.50M | 8 | 2026-08-31 |
| SKYE | Director | 6,901 | $2.04 | $14.1K | -$2.69M | 7 | 2026-08-20 |
| TRDA | 10%+ Owner | 3,941,623 | $6.80 | $26.80M | -$4.84M | 1 | 2026-08-03 |
| ARTV | 10%+ Owner | 1,182,054 | $10.22 | $12.08M | $60.00M | 1 | 2024-07-24 |
| Enliven Therapeutics, Inc. (IMRA) Delisted | Director | 3,888,992 | $14.59 | $56.74M | -$45.00M | 3 | 2024-02-02 |
| Pear Therapeutics, Inc. (PEARW) Delisted | Director | 12,989,936 | $0.01 | $76.6K | -$8.38M | 2 | 2022-09-16 |
| RLYB | 10%+ Owner | 162,760 | $16.88 | $2.75M | -$7.80M | 1 | 2022-05-25 |
| IPI Legacy Liquidation Co (IMPL) Delisted | 10%+ Owner | 1,849,456 | $0.24 | $445.9K | $60.38M | 1 | 2021-04-29 |
| CABA | 10%+ Owner | 380,218 | $2.73 | $1.04M | -$35.22M | 1 | 2021-01-12 |
| 5:01 Acquisition Corp. (FVAM) Delisted | Co-CEO | 365,126 | $10.00 | $3.65M | $0 | 4 | 2020-12-01 |
| scPharmaceuticals Inc. (SCPH) Delisted | 10%+ Owner | 3,123,303 | $5.67 | $17.71M | $5.00M | 1 | 2020-05-28 |
| ARVN | 10%+ Owner | 3,888,216 | $8.45 | $32.86M | -$106.29M | 2 | 2019-07-01 |
| CRNX | 94,489 | $84.95 | $8.03M | -$33.30M | 1 | 2019-06-25 | |
| FIXX | 10%+ Owner | 1,367 | $13.72 | $18.8K | -$82.79M | 2 | 2019-05-20 |
| EPIRUS Biopharmaceuticals, Inc. (EPRS) Delisted | 10%+ Owner | 65,699 | — | — | $10.00M | 1 | 2015-02-06 |
| FLXN | Director | 1,512,076 | $24.62 | $37.23M | $0 | 2 | 2014-03-04 |
Recent Filings
44 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-08-31 | CAMP | Sell (S) | −400,000 | -$1.62M | EDGAR |
| 2026-08-26 | CAMP | Sell (S) | −10 | -$45 | EDGAR |
| 2026-08-21 | CAMP | Sell (S) | −191,865 | -$879.7K | EDGAR |
| 2026-08-20 | SKYE | Sell (S) | −375,840 | -$140.3K | EDGAR |
| 2026-08-05 | CAMP | Grant (A) | — | $0 | EDGAR |
| 2026-08-03 | TRDA | Sell (S) | −698,844 | -$4.84M | EDGAR |
| 2026-06-12 | CAMP | Grant (A) | — | $0 | EDGAR |
| 2026-04-02 | SKYE | Grant (A) | — | $0 | EDGAR |
| 2026-02-09 | SKYE | Grant (A) | — | $0 | EDGAR |
| 2025-09-15 | CAMP | Grant (A) | +2,941,176 | $4.50M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.